AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Immuron Limited
Video analysis: IMRN
All videosNo video analysis for this stock yet. Request one from our team.
News: IMRN
Immuron Stock Surges Friday: What's Driving the Action?
Shares of Immuron Limited (NASDAQ:IMRN) are surging Friday morning following news that the Australian biopharmaceutical company signed an exclusive agreement to launch PROIBS gut health product in the United States. Here's what investors need to know.
Immuron to launch PROIBS® in the United States
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26.
Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) Financial Analysis
Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Immuron (NASDAQ: IMRN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk. Analyst Recommendations This is a breakdown of recent
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application IND 32095 is Immuron's Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529. Pullan Consulting is a highly regarded life sciences advisory firm with a strong track record of executing between five and twelve partnering transactions annually over the past 20 years.
